Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
Date:5/2/2013

t could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of nonclinical, preclinical and toxicology studies, result of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies To Present At The 25th Annual ROTH Conference
2. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
3. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
5. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
6. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
8. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... at the Cambridge University have discovered that freshwater algae ... each other, miraculously held together only by the fluid ... today in the journal Physical Review Letters . ... consists of approximately 1,000 cells arranged on the surface ...
... Kendle (Nasdaq: KNDL ), a leading, global ... not meet analyst expectations for the first quarter of ... unprecedented biopharmaceutical industry conditions, which are resulting in longer ... fewer new requests for proposals and an increase in ...
... --BRISBANE, Calif., April 20 InterMune, Inc. (Nasdaq: ... host a live webcast of a discussion of the INFORM-1 ... at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in ... the INFORM-1 trial. Members of management from Roche, InterMune ...
Cached Biology Technology:Scientists discover 'dancing' algae 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 3InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... CAMBRIDGE, Mass. (April 2, 2009) Whitehead Institute researchers have ... have further clarified the role prions play in the inheritance ... in the field is are the prions functional are ... disease, as in "mad cow," disease in mammals," says Randal ...
... Since the days of Charles Darwin, researchers are interested ... the development of animal and plant species during their ... has already come quite a long way. But there ... animal groups that made their apparation very early in ...
... directly affect human survival and food security, especially as ... groups of social insects to cultivate crops, have harvested ... 50 million years. New results from the Smithsonian show ... combat fungi coming into the nest inside leaves, thus ...
Cached Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Early family ties: No sponge in the human family tree 2Early family ties: No sponge in the human family tree 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Goat anti-mouse gamma chain-HRP...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Biology Products: